

SAFETY DATA SHEETS

This SDS packet was issued with item:

078056437

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078921838

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078056429



UPDATED PRODUCT CODE: 066999 -12.5mg
VERSION DATE: 6/2007

Page 1 of 4

MATERIAL SAFETY DATA SHEET

1. CHEMICAL PRODUCT and COMPANY IDENTIFICATION

Product Name: SALIX™
Product Family: PHARMACEUTICALS

PRODUCT:

SALIX™ TABLETS

PRODUCT CODE:

066999 - 12.5 mg

SYNONYMS:

FUROSEMIDE

PRODUCT USE: Refer to product insert for proper usage.

COMPANY ADDRESS - Intervet Inc - 29160 Intervet Lane - Millsboro, DE 19966

2. COMPOSITION / INFORMATION on INGREDIENTS

HAZARDOUS COMPONENT:

CONCENTRATION:

CAS NUMBER:

FUROSEMIDE LIQUID

1.0%-5.0%

54-31-9

FUROSEMIDE TABLETS

12.5MG-50MG

54-31-9

3. HAZARDS IDENTIFICATION

EMERGENCY OVERVIEW: Warning: Milk taken from animals during treatment and for forty-eight hours (four milkings) after the last treatment must not be used for food. Cattle must not be slaughtered for food within forty-eight hours following the last treatment.

SIGNS AND SYMPTOMS OF EXPOSURE: In animals, signs of acute toxicity include lethargy, prostration, diuresis, and weight loss. In humans diuresis should be the first sign of exposure. Excessive diuresis may result in dehydration, hypokalemia, hypocalcemia and orthostatic hypotension. Other symptoms include weakness, fatigue and malaise.

EMERGENCY: HUMAN, FIRE, SPILL OR ENVIRONMENTAL: 1-800-228-5635 EXT. 132 24 HRS.
ANIMAL: 1-800-345-4735 EXT. 104 24 HRS.
CHEMTREC® FOR CHEMICAL EMERGENCY SPILL, LEAK, FIRE: 1-800-424-9300

PRODUCT INFORMATION: 1-800-835-0541 OR 1-302-934-8051 9:00 A.M. – 5:00 P.M. EST



UPDATED PRODUCT CODE: 066999 -12.5mg
VERSION DATE: 6/2007

Page 2 of 4

ROUTES OF ENTRY: *Dermal, Injection, Inhalation, Ingestion*

ACUTE EFFECTS OF EXPOSURE: *May cause irritation at site of contact.*

CHRONIC EFFECTS OF EXPOSURE: *None known*

TARGET ORGAN EFFECTS: *Kidney. Furosemide inhibits the absorption of sodium and chlorine in the proximal and distal tubules, and in the loop of Henley.*

CARCINOGENIC EFFECTS: *This product is not considered a carcinogen and is not listed by OSHA, IRA or NTT.*

----- 4. FIRST AID MEASURES -----

Treatment is symptomatic and includes replacement of fluid and electrolytes.

SKIN: *Wash immediately affected area with soap and water. Contact a physician.*

EYES: *Immediately flush with plenty of water for fifteen minutes. Contact a physician.*

INHALATION: *Remove to fresh air. If not breathing, give artificial respiration and call for medical help immediately.*

INGESTION: *Seek medical attention immediately.*

----- 5. FIRE FIGHTING MEASURES -----

FLAMMABILITY: *Not Available*

EXTINGUISHING METHODS: *Use Water, Water Mist, Foam or Dry Chemical to extinguish fire.*

FIRE FIGHTING INSTRUCTIONS: *Wear full bunker gear, including SCBA. Keep upwind.*

----- 6. ACCIDENTAL RELEASE MEASURES -----

PROCEDURES IN CASE OF SPILL OR LEAK: *Minor spillage may be flushed away with water. Large volume spills should be collected in salvage containers and should be incinerated in accordance with local, state and federal regulations.*

----- 7. HANDLING and STORAGE -----

EMERGENCY: HUMAN, FIRE, SPILL OR ENVIRONMENTAL: 1-800-228-5635 EXT. 132 24 HRS.
ANIMAL: 1-800-345-4735 EXT. 104 24 HRS.
CHEMTREC® FOR CHEMICAL EMERGENCY SPILL, LEAK, FIRE: 1-800-424-9300

PRODUCT INFORMATION: 1-800-835-0541 OR 1-302-934-8051 9:00 A.M. – 5:00 P.M. EST



UPDATED PRODUCT CODE: 066999 -12.5mg
VERSION DATE: 6/2007

Page 3 of 4

STORAGE: Store at room temperature (below 25C) in well-closed containers with safety closures. The product should be colorless to slightly brown. Do not use if solution is discolored. Product is light sensitive.

SHELF LIFE: See expiration date on product label.

HANDLING PRECAUTIONS: See product label.

----- 8. EXPOSURE CONTROL / PERSONAL PROTECTION -----

Furosemide Workplace Exposure Limit: (interim) 0.5mg/m³

EYES: Prevent eye contact by wearing appropriate eye protection for handling tasks.

SKIN: Avoid skin contact. Wear chemical resistant gloves, long-sleeves and trousers to prevent dermal contact.

RESPIRATOR PROTECTION: Under normal conditions of use, as stated in the product insert, no respiratory protection is necessary. However, if ventilation is inadequate wear a NIOSH approved respirator.

----- 9. PHYSICAL and CHEMICAL PROPERTIES -----

APPEARANCE: 50mL vials, 12.5mg yellow tablet, or 50mg yellow tablet

PH: 7.0-7.8

----- 10. STABILITY and REACTIVITY -----

CHEMICAL STABILITY: Stable

CONDITIONS TO AVOID: None known

INCOMPATIBILITY: None Known

HAZARDOUS POLYMERIZATION: Will not occur

----- 11. TOXICOLOGICAL INFORMATION -----

EMERGENCY: HUMAN, FIRE, SPILL OR ENVIRONMENTAL: 1-800-228-5635 EXT. 132 24 HRS.
ANIMAL: 1-800-345-4735 EXT. 104 24 HRS.
CHEMTREC® FOR CHEMICAL EMERGENCY SPILL, LEAK, FIRE: 1-800-424-9300

PRODUCT INFORMATION: 1-800-835-0541 OR 1-302-934-8051 9:00 A.M. – 5:00 P.M. EST



UPDATED PRODUCT CODE: 066999 -12.5mg
VERSION DATE: 6/2007

Page 4 of 4

Oral LD 50 Rat: 4600 mg/kg
Intraperitoneal LD50 (rat): Not available
Intraperitoneal LD50 (mouse): Not available

12. ECOLOGICAL INFORMATION

ECOTOXICITY: *Salix (Furosemide)* administered to animals presents negligible impact on the environment.

13. DISPOSAL CONSIDERATIONS

Minor spillage may be flushed away with water. Large volume spills should be collected in salvage containers and should be incinerated in accordance with local, state and federal regulations.

14. TRANSPORTATION

DOT SHIPPING INFORMATION: Not regulated by the DOT

15. REGULATORY INFORMATION

US FEDERAL REGULATIONS: *Salix (Furosemide)* is regulated under the US FDA.

16. OTHER INFORMATION

DISCLAIMER:

The information contained herein is true and accurate to the best of the knowledge of Intervet Inc. However, all data, instructions and/or recommendations are made without guarantee. The buyer and handler assume all risk and liability of use, storage and/or handling of this product not in accordance with the terms of the product label.

EMERGENCY: HUMAN, FIRE, SPILL OR ENVIRONMENTAL: 1-800-228-5635 EXT. 132 24 HRS.
ANIMAL: 1-800-345-4735 EXT. 104 24 HRS.
CHEMTREC® FOR CHEMICAL EMERGENCY SPILL, LEAK, FIRE: 1-800-424-9300

PRODUCT INFORMATION: 1-800-835-0541 OR 1-302-934-8051 9:00 A.M. – 5:00 P.M. EST

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
3.2	04/12/2018	632214-00006	Date of first issue: 05/03/2016

SECTION 1. IDENTIFICATION

Product name : Furosemide Injection Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033

Telephone : 908-740-4000

Telefax : 908-735-1496

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with 29 CFR 1910.1200**

Specific target organ : Category 1 (Kidney, Liver)
systemic toxicity - repeated
exposure

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H372 Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**
P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

Response:
P314 Get medical advice/ attention if you feel unwell.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
3.2	04/12/2018	632214-00006	Date of first issue: 05/03/2016

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Furosemide	54-31-9	$\geq 5 - < 10$

SECTION 4. FIRST AID MEASURES

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately., When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Get medical attention if symptoms occur.
In case of eye contact	: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Causes damage to organs through prolonged or repeated exposure.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists.
Notes to physician	: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Exposure to combustion products may be a hazard to health.

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
3.2	04/12/2018	632214-00006	Date of first issue: 05/03/2016

Hazardous combustion products	: Nitrogen oxides (NO _x) Carbon oxides Sulfur oxides Chlorine compounds
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.
Environmental precautions	: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	: Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: Use only with adequate ventilation.
Advice on safe handling	: Avoid inhalation of vapor or mist. Do not swallow.

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
3.2	04/12/2018	632214-00006	Date of first issue: 05/03/2016

Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Furosemide	54-31-9	TWA	200 µg/m ³	Internal
		TWA	OEB 2 (>=100 - 1000 µg/m ³)	Internal

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection
Material : Chemical-resistant gloves

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
3.2	04/12/2018	632214-00006	Date of first issue: 05/03/2016

- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.
- Hygiene measures : Ensure that eye flushing systems and safety showers are located close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
-

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : Aqueous solution
- Color : yellow
- Odor : No information available.
- Odor Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : No data available
- Evaporation rate : No data available
- Flammability (solid, gas) : Not applicable
- Flammability (liquids) : No data available
- Upper explosion limit / Upper flammability limit : No data available
- Lower explosion limit / Lower flammability limit : No data available
- Vapor pressure : No data available
- Relative vapor density : No data available

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
3.2	04/12/2018	632214-00006	Date of first issue: 05/03/2016

Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle size	:	Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg
---------------------	---	--

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
3.2	04/12/2018	632214-00006	Date of first issue: 05/03/2016

Method: Calculation method

Components:**Furosemide:**

Acute oral toxicity : LD50 (Rat): 2,600 mg/kg
LD50 (Dog): 2,000 mg/kg
LD50 (Rabbit): 800 mg/kg

Acute toxicity (other routes of administration) : LD0 (Humans): 6 - 29 mg/kg
Application Route: Intravenous
LD50 (Rat): 800 mg/kg
Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:**Furosemide:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: mouse lymphoma cells
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: mammalian liver cells
Result: negative

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Result: positive

Test Type: In vitro sister chromatid exchange assay in mammalian cells

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
3.2	04/12/2018	632214-00006	Date of first issue: 05/03/2016

Test system: Chinese hamster cells

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Chinese hamster
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Furosemide:**

Species : Rat
Application Route : Ingestion
Exposure time : 104 weeks
LOAEL : 16 mg/kg body weight
Result : equivocal

Species : Mouse
Application Route : Ingestion
Exposure time : 2 Years
LOAEL : 91 mg/kg body weight
Result : positive

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:**Furosemide:**

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
General Toxicity Parent: NOAEL: 90 mg/kg body weight
Result: No effects on reproduction parameters.

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
3.2	04/12/2018	632214-00006	Date of first issue: 05/03/2016

Test Type: One-generation reproduction toxicity study
Species: Mouse
Application Route: Ingestion
General Toxicity Parent: NOAEL: 200 mg/kg body weight
Result: No effects on reproduction parameters.

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 50 mg/kg body weight
Developmental Toxicity: NOAEL: 300 mg/kg body weight
Result: No embryotoxic effects., No teratogenic effects.

Test Type: Fertility/early embryonic development
Species: Mouse
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 25 mg/kg body weight
Result: Maternal toxicity observed., Fetal effects.

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Ingestion
General Toxicity Maternal: LOAEL: <= 12 mg/kg body weight
Developmental Toxicity: LOAEL: 12.5 mg/kg body weight
Result: Maternal toxicity observed., Reduced number of viable fetuses.

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 15 mg/kg body weight
Result: Maternal toxicity observed., No effects on fetal development.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Components:**Furosemide:**

Routes of exposure	: Ingestion
Target Organs	: Kidney
Assessment	: Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

Repeated dose toxicity**Components:****Furosemide:**

Species	: Dog
NOAEL	: 4 mg/kg

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
3.2	04/12/2018	632214-00006	Date of first issue: 05/03/2016

LOAEL	:	8 mg/kg
Application Route	:	Ingestion
Exposure time	:	12 Months
Target Organs	:	Kidney
Symptoms	:	Blood disorders
Remarks	:	Significant toxicity observed in testing

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Furosemide:**

Inhalation	:	Remarks: May be harmful if inhaled.
Skin contact	:	Remarks: May irritate skin.
Eye contact	:	Remarks: May cause eye irritation.
Ingestion	:	Symptoms: Kidney disorders, Headache, electrolyte imbalance, dry mouth, hearing loss, Irregular cardiac activity, Gastrointestinal disturbance, hypotension

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Furosemide:**

Toxicity to fish	:	LC50: 500 mg/l Exposure time: 96 h
------------------	---	---------------------------------------

Persistence and degradability

No data available

Bioaccumulative potential**Components:****Furosemide:**

Partition coefficient: n-octanol/water	:	log Pow: 2.03
--	---	---------------

Mobility in soil

No data available

Other adverse effects

No data available

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
3.2	04/12/2018	632214-00006	Date of first issue: 05/03/2016

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**49 CFR**

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION**EPCRA - Emergency Planning and Community Right-to-Know****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations**Pennsylvania Right To Know**

Water	7732-18-5
Furosemide	54-31-9

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
3.2	04/12/2018	632214-00006	Date of first issue: 05/03/2016

California Prop. 65

This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.


The ingredients of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



HMIS® IV:

HEALTH	*	3
FLAMMABILITY		1
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Oth-

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
3.2	04/12/2018	632214-00006	Date of first issue: 05/03/2016

erwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/12/2018

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
5.2	09/13/2019	645633-00008	Date of first issue: 05/03/2016

SECTION 1. IDENTIFICATION

Product name : Furosemide Solid Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033
Telephone : 908-740-4000
Telefax : 908-735-1496
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with 29 CFR 1910.1200**

Combustible dust

Specific target organ toxicity : Category 1 (Kidney, Liver)
- repeated exposure

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
H372 Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

Response:
P314 Get medical advice/ attention if you feel unwell.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
5.2	09/13/2019	645633-00008	Date of first issue: 05/03/2016

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Starch	9005-25-8	$\geq 50 - < 70$
Furosemide	54-31-9	$\geq 10 - < 20$
Cellulose	9004-34-6	$\geq 1 - < 5$

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Get medical attention if symptoms occur.
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Causes damage to organs through prolonged or repeated exposure. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
5.2	09/13/2019	645633-00008	Date of first issue: 05/03/2016

Hazardous combustion products	:	Nitrogen oxides (NO _x) Carbon oxides Sulfur oxides Chlorine compounds
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.
Environmental precautions	:	Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

Furosemide Solid Formulation

Version 5.2 Revision Date: 09/13/2019 SDS Number: 645633-00008 Date of last issue: 04/24/2019
 Date of first issue: 05/03/2016

- assessment
 Minimize dust generation and accumulation.
 Keep container closed when not in use.
 Keep away from heat and sources of ignition.
 Take precautionary measures against static discharges.
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents
 Organic peroxides
 Explosives
 Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Starch	9005-25-8	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
Furosemide	54-31-9	TWA	200 µg/m ³	Internal
		TWA	OEB 2 (>=100 - 1000 µg/m ³)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1

- Engineering measures** : Use feasible engineering controls to minimize exposure to compound.
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

- Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn.

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
5.2	09/13/2019	645633-00008	Date of first issue: 05/03/2016

Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection
Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : yellow

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
5.2	09/13/2019	645633-00008	Date of first issue: 05/03/2016

Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	Not applicable
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
5.2	09/13/2019	645633-00008	Date of first issue: 05/03/2016

Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:**Starch:**

Acute oral toxicity : LD50 (Mouse): > 5,000 mg/kg

Furosemide:

Acute oral toxicity : LD50 (Rat): 2,600 mg/kg

LD50 (Dog): 2,000 mg/kg

LD50 (Rabbit): 800 mg/kg

Acute toxicity (other routes of administration) : LD0 (Humans): 6 - 29 mg/kg
Application Route: Intravenous

LD50 (Rat): 800 mg/kg
Application Route: Intravenous

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
5.2	09/13/2019	645633-00008	Date of first issue: 05/03/2016

Components:**Furosemide:**

- Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
- Test Type: In vitro mammalian cell gene mutation test
Test system: mouse lymphoma cells
Result: positive
- Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: mammalian liver cells
Result: negative
- Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Result: positive
- Test Type: In vitro sister chromatid exchange assay in mammalian cells
Test system: Chinese hamster cells
Result: negative
- Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative
- Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Chinese hamster
Application Route: Ingestion
Result: negative

Cellulose:

- Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
- Test Type: In vitro mammalian cell gene mutation test
Result: negative
- Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
5.2	09/13/2019	645633-00008	Date of first issue: 05/03/2016

Components:**Furosemide:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	104 weeks
LOAEL	:	16 mg/kg body weight
Result	:	equivocal

Species	:	Mouse
Application Route	:	Ingestion
Exposure time	:	2 Years
LOAEL	:	91 mg/kg body weight
Result	:	positive

Cellulose:

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	72 weeks
Result	:	negative

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:**Furosemide:**

Effects on fertility	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion General Toxicity Parent: NOAEL: 90 mg/kg body weight Result: No effects on reproduction parameters.
----------------------	---	---

	:	Test Type: One-generation reproduction toxicity study Species: Mouse Application Route: Ingestion General Toxicity Parent: NOAEL: 200 mg/kg body weight Result: No effects on reproduction parameters.
--	---	--

Effects on fetal development	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion General Toxicity Maternal: LOAEL: 50 mg/kg body weight Developmental Toxicity: NOAEL: 300 mg/kg body weight Result: No embryotoxic effects., No teratogenic effects.
------------------------------	---	--

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
5.2	09/13/2019	645633-00008	Date of first issue: 05/03/2016

Test Type: Fertility/early embryonic development
Species: Mouse
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 25 mg/kg body weight
Result: Maternal toxicity observed., Fetal effects.

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Ingestion
General Toxicity Maternal: LOAEL: <= 12 mg/kg body weight
Developmental Toxicity: LOAEL: 12.5 mg/kg body weight
Result: Maternal toxicity observed., Reduced number of viable fetuses.

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 15 mg/kg body weight
Result: Maternal toxicity observed., No effects on fetal development.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Components:**Furosemide:**

Routes of exposure : Ingestion
Target Organs : Kidney
Assessment : Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

Repeated dose toxicity**Components:****Furosemide:**

Species : Dog
NOAEL : 4 mg/kg

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
5.2	09/13/2019	645633-00008	Date of first issue: 05/03/2016

LOAEL	:	8 mg/kg
Application Route	:	Ingestion
Exposure time	:	12 Months
Target Organs	:	Kidney
Symptoms	:	Blood disorders
Remarks	:	Significant toxicity observed in testing

Cellulose:

Species	:	Rat
NOAEL	:	>= 9,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Furosemide:**

Inhalation	:	Remarks: May be harmful if inhaled.
Skin contact	:	Remarks: May irritate skin.
Eye contact	:	Remarks: May cause eye irritation.
Ingestion	:	Symptoms: Kidney disorders, Headache, electrolyte imbalance, dry mouth, hearing loss, Irregular cardiac activity, Gastrointestinal disturbance, hypotension

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Furosemide:**

Toxicity to fish	:	LC50: 500 mg/l
	:	Exposure time: 96 h

Cellulose:

Toxicity to fish	:	LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
	:	Exposure time: 48 h
	:	Remarks: Based on data from similar materials

Persistence and degradability**Components:****Cellulose:**

Biodegradability	:	Result: Readily biodegradable.
------------------	---	--------------------------------

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
5.2	09/13/2019	645633-00008	Date of first issue: 05/03/2016

Bioaccumulative potential**Components:****Furosemide:**

Partition coefficient: n-octanol/water : log Pow: 2.03

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**49 CFR**

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION**EPCRA - Emergency Planning and Community Right-to-Know****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
5.2	09/13/2019	645633-00008	Date of first issue: 05/03/2016

Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Starch	9005-25-8
D-Glucose, 4-O-.beta.-D-galactopyranosyl-, monohydrate	64044-51-5
Furosemide	54-31-9
Cellulose	9004-34-6

California Permissible Exposure Limits for Chemical Contaminants

Starch	9005-25-8
Cellulose	9004-34-6


The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



HMIS® IV:

HEALTH	*	3
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	: USA. NIOSH Recommended Exposure Limits
OSHA Z-1	: USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	: 8-hour, time-weighted average

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
5.2	09/13/2019	645633-00008	Date of first issue: 05/03/2016

NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek

OSHA Z-1 / TWA : 8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 09/13/2019

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
5.2	09/13/2019	645633-00008	Date of first issue: 05/03/2016

US / Z8